Symphony Capital

Symphony Capital is a healthcare-focused private equity firm that pioneered a unique collaborative financing model for the biopharmaceutical industry. The firm specialized in providing non-dilutive capital to fund the clinical development of late-stage drug candidates through the creation of "Symphony" companies. These entities were typically structured to advance specific programs from major biotech and pharma partners, such as Exelixis and Alexion, with the partner retaining an option to re-acquire the programs upon reaching clinical milestones. This model allowed companies to accelerate their pipelines while managing financial risk and balance sheet impact. Notable successes from their portfolio include the development of Soliris (eculizumab) and Dalvance (dalbavancin).